U.S. markets closed

DBV Technologies S.A. (DBVT)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
6.19-0.03 (-0.48%)
At close: 4:00PM EDT

6.19 0.00 (0.00%)
After hours: 4:00PM EDT

Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Intermediate-term KST

Intermediate-term KST

Previous Close6.22
Open6.16
Bid5.77 x 800
Ask6.29 x 3000
Day's Range6.15 - 6.28
52 Week Range1.35 - 7.38
Volume77,099
Avg. Volume152,336
Market Cap697.297M
Beta (5Y Monthly)2.22
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • InvestorPlace

    DBVT Stock: DBV Technologies Soars on Big Peanut Allergy Patch News

    DBV Technologies (NASDAQ:DBVT) stock is soaring higher on Friday after providing an update on its peanut allergy treatment. Source: Crown World / Shutterstock.com DBV Technologies is working on a product called Viaskin Peanut to treat peanut allergies in children between the ages of four and 11 years old. The company says that its communications with the U.S. Food and Drug Administration (FDA) so far have been positive. According to a news release from DBV Technologies, its working alongside the FDA to alter the patch. It plans to do so and conduct a clinical trial determining the effectiveness of the new patch and other changes.InvestorPlace - Stock Market News, Stock Advice & Trading Tips The company makes sure to note that these changes won’t result in the FDA viewing the updated patch as a new drug. That gives the company a clear path forward for regulatory approval of Viaskin Peanut. 9 Stocks That Investors Think Are the Next Amazon Daniel Tassé, CEO of DBV Technologies, said this about the news boosting DBVT stock higher today. “I want to thank the DBV team for their dedication in working to address the FDA’s findings over the past few months. We intend to advance a remediation plan for Viaskin™ Peanut and work closely with FDA to review protocols and re-file our BLA as soon as possible, so that we can bring Viaskin™ Peanut, if approved, to patients suffering from peanut allergies.” DBV Technologies plans to selected updated patches in Q1 2021. It will then seek FDA comments in Q2 2021 before starting its next clinical trial. DBVT stock was up 42.1% as of Friday morning. On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. More From InvestorPlace Why Everyone Is Investing in 5G All WRONG Top Stock Picker Reveals His Next 1,000% Winner It doesn’t matter if you have $500 in savings or $5 million. Do this now. The post DBVT Stock: DBV Technologies Soars on Big Peanut Allergy Patch News appeared first on InvestorPlace.

  • TheStreet.com

    DBV Technologies Spikes on Positive FDA Communication

    Shares of microcap biopharmaceutical company DBV Technologies jumped more than 40% Friday after the company said it received positive responses from the U.S. Food and Drug Administration regarding its application for a peanut allergy treatment. The U.S. FDA provided type A meeting requests to the questions the French company submitted in October following its receipt of a complete response letter in connection with its biologics license application (BLA) for Viaskin Peanut DBV712, its once-daily epicutaneous patch to treat peanut allergy in children ages four to 11. "We are very encouraged by the positive feedback received from the FDA, and we appreciate the clarity provided," said Daniel Tassé, CEO of DBV Technologies.

  • DBV Technologies SA (DBVT) Fell Out Of Favor With Hedge Funds
    Insider Monkey

    DBV Technologies SA (DBVT) Fell Out Of Favor With Hedge Funds

    In this article you are going to find out whether hedge funds think DBV Technologies SA (NASDAQ:DBVT) is a good investment right now. We like to check what the smart money thinks first before doing extensive research on a given stock. Although there have been several high profile failed hedge fund picks, the consensus picks […]